SpyGlass Pharma's intraocular drug delivery platform is designed to be implanted in glaucoma patients at the time of routine cataract surgery and deliver multiple years of bimatoprost for lowering intraocular pressure (IOP). Now, a prospective, multicenter, randomized, phase 1/2 study is under way to evaluate the platform — bimatoprost implanted with the SpyGlass intraocular lens (IOL) during cataract surgery — compared with a control group receiving a commercially available IOL plus IOP-lowering drops.

“Our platform has the potential to meaningfully improve care for patients living with glaucoma," said Malik Y. Kahook, MD, cofounder, executive chair, and president of SpyGlass Pharma in a news release. "We were pleased to receive clearance from the FDA to initiate our clinical trial and look forward to advancing this important study.”

Patients receiving the SpyGlass IOL with bimatoprost in the previous first-in-human feasibility study experienced a consistent 45% mean reduction in IOP at 9 months.